Steeper Change in Body Mass Across Four Decades Predicts Poorer Cardiometabolic Outcomes at Midlife

Hong Xian¹, Terrie Vasilopoulos², Weijian Liu¹, Richard L. Hauger³,⁴, Kristen C. Jacobson⁵, Michael J. Lyons⁶, Matthew Panizzon³, Chandra A. Reynolds⁶, Eero Vuoksimaa⁸, William S. Kremen³,⁴*, and Carol E. Franz³*

Objective: This study examined patterns of change in adiposity across four decades starting in young adulthood as well as associations between change and midlife cardiometabolic outcomes.

Methods: BMI was assessed at ages 20, 40, 56, and 62 years in 977 male veterans from the Vietnam Era Twin Study of Aging. Age 62 (range 56-66) cardiometabolic outcomes included hypertension, diabetes, dyslipidemia, inflammation, and ischemic heart disease. Analyses included latent growth modeling (LGM), latent class growth modeling (LCGM), and logistic regression models.

Results: Linear BMI slope was associated with all outcomes. Accelerated (quadratic) BMI slope was significantly associated with greater risk for hypertension, diabetes, dyslipidemia, and inflammation; odds ratios ranged from 1.93 (diabetes) to 3.15 (dyslipidemia). Initial BMI did not predict later outcomes. Linear slope contributed significant unique variance for diabetes and dyslipidemia even controlling for age 62 BMI. LCGM revealed three trajectories. Men with the relatively stable, lower BMI trajectory had significantly better outcomes than those with trajectories with accelerated increases, especially those including obesity.

Conclusions: How individuals reach late-midlife BMI is important. Steepness of BMI change across 40 years from young adulthood to late midlife, in addition to late-midlife BMI itself, was robustly associated with greater risk for poor cardiometabolic outcomes.

Obesity (2017) 25, 773-780. doi:10.1002/oby.21791

Introduction

Obesity poses a serious public health concern (1,2). It has been established as a prominent risk factor for cardiovascular disease (CVD), the leading cause of morbidity and mortality among adults in the United States, and is linked to many detrimental cardiometabolic outcomes (2-6). In the Framingham Heart Study, higher adiposity at approximately age 50 (midlife) was associated with reduced survival and 52% higher lifetime risk for CVD by age 95; men with no cardiometabolic risk factors at midlife were highly unlikely to develop heart disease in late life (5).

Midlife is a transitional period for men’s health, with rapid increases in rates of CVD, high cholesterol, diabetes, and hypertension after age 50; moreover, over half of deaths due to CVD occur in men (7). Measured rates of body mass index (BMI), an indicator of adiposity, in adult men age 20 and over in the United States indicate that age-adjusted obesity (BMI ≥ 30 kg/m²) rose progressively from an estimated 31.6% in 1999-2002 to 35.5% in 2009-2010 (8). From 2005 to 2014, age-adjusted obesity rates appeared to stabilize in adult men (9).

Longitudinal patterns of change in adiposity are understudied, in particular the period from young adulthood (ages 19-29) through midlife (ages 45-64). One study identified four longitudinal BMI trajectories from age 18 to age 49 years (10); self-reports of hypertension, diabetes, and high cholesterol were lowest in the normal BMI trajectory and highest in the two trajectories that included obesity. Studies of adults across shorter periods of time demonstrated mixed associations between change in BMI and various CVD risk factors (11-14). In earlier studies by our group, being overweight in young adulthood significantly predicted age 48 diabetes but not hypertension (14). In addition, we found significant shared genetic and...
environmental influences between adiposity and all other components of the metabolic syndrome (i.e., hypertension, insulin resistance, cholesterol, triglycerides) (15). Adiposity was the only component genetically associated with all other components.

Objectives of this study were (a) to assess change and patterns of change in adiposity from young adulthood to late midlife (age 62 years); and (b) to examine associations between change in adiposity and late-midlife cardiometabolic outcomes. We hypothesized that a steeper BMI slope over time would be associated with higher rates of diabetes, dyslipidemia, heart disease, hypertension, and inflammation.

Methods
Participants were 977 men in the Vietnam Era Twin Study of Aging follow-up assessment (VETSA 2; mean age 61.6 years [range 56-66]) with complete data (16). The VETSA project is a longitudinal study of risk and protective factors for cognitive aging in a community-dwelling sample of veterans from across the United States.

Recruitment
In the first VETSA assessment (VETSA 1: 2002-2008), the 1,237 participants (mean age 56 years; range 51-60) were a simple random sample from the all-male Vietnam Era Twin Registry (VETR) (17). The VETR was established as a research registry of twins who had both served in the US military between 1965 and 1975. VETSA 1 eligibility included being 51 to 59 years old when recruited and both members of a twin pair agreeing to participate (18). Recruitment rate was 44%; we view this positively, as the study involved high burden—a three-day/two-night commitment due to travel to University of California, San Diego (UCSD) or Boston University (BU) for assessment, limited enrollment windows (due to batching), and the requirement that both brothers enroll. Ethical approval of the research protocol was provided by the UCSD Human Research Protection Program and the BU Charles River Campus Institutional Review Board. More details about the recruitment and methods are in online Supporting Information.

The VETSA 2 follow-up occurred approximately 6 years after VETSA 1 (2008-2014); 1,016 men from VETSA 1 participated in the follow-up (82% retention). The most common single reason for attrition was death (N = 56).

The VETSA participants make up a relatively representative epidemiological sample of community-based men with regard to marital, work, income, and health characteristics of American men in their age range based on US Census and Centers for Disease Control and Prevention (CDC) data (19). Prevalence of self-reported chronic health problems was also generally comparable with CDC rates for men. VETSA participants constitute a sample with no major chronic childhood health problems.

Procedures
The VETR also serves as a data archive for data previously collected on the registry sample; those data are available to other researchers on request. This study incorporates data from four data collections: military induction data procured from military records by the VETR and a National Heart, Lung, and Blood Institute-funded study conducted in 1990 (20) (both archived at the VETR), as well as the two waves of VETSA data collection conducted by our research group (16).

Height, weight, pulse, and blood pressure (BP) were measured objectively at military induction (mean age 20 years; range 17-25). Height and weight at mean age 40 years (range 35-46) were collected with a self-report health survey mailed to all VETR twins in 1990 as part of a National Heart, Lung, and Blood Institute-funded study (20). Relevant military record and 1990 survey data were provided to VETSA researchers by the VETR.

VETSA 1 and 2 data were collected in person at either UCSD or BU. Height, weight, pulse, and BP were measured objectively. Blood chemistries were only obtained in VETSA 2 (15). Participants who did not fast for at least 9 hours were excluded from analyses. Following written informed consent, blood was drawn by a certified phlebotomist. Assays were conducted at the same certified laboratory to ensure comparability (Quest Diagnostics/Nichols Institute, San Juan Capistrano, California).

From here forward, we refer to data collection time points as age 20 (or baseline), age 40, age 56, and age 62.

Measures
BMI. Height and weight were measured at age 20; at that time, the majority of men did not have obesity (2.3% [n = 22] men with BMI ≥ 30 kg/m²) (17). Age 40 height and weight were self-reported. Self-reported height and weight are considered valid measures but are biased toward underreport of weight (especially in women, overweight adults, and adults over age 45) and overreport of height (21,22). At ages 56 and 62, participants were weighed on a digital scale after removing shoes and heavy outer clothing. Height was assessed, in stocking feet, with a stadiometer. Self-reported height at age 40 correlated r = 0.94 with measured height at age 56; measured height at ages 56 and 62 correlated r = 0.96. Age 40 self-reported weight correlated r = 0.86 with weight at age 56; measured weight at ages 56 and 62 correlated r = 0.92.

After being transformed to metric scales, BMI was calculated as kg/m². BMI ranges are: normal, 18.5 to 24.9; overweight, 25.0 to 29.9; level 1 obesity, 30.0 to 34.9; level 2 obesity, 35.0 to 39.9; and level 3 obesity, 40.0 and greater (23). More details about BMI measurements are available elsewhere (14,15). BMI was our only indicator of adiposity with data from four time points. From this point forward, we refer to BMI at age 20 and age 62 as BMI20 and BMI62.

Age 62 (VETSA 2) cardiometabolic measures.
Hypertension. Age 62 BP was based on the average of four systolic BP readings and four diastolic BP readings taken during the assessment day. In the morning and afternoon, after sitting quietly for 5 minutes, BP was taken twice with an automated blood pressure machine with a 1-minute break between readings. Individuals with either systolic BP > 140 or diastolic BP > 90 mm Hg (24), or who took antihypertensive medication, were classified as hypertensive (75.1%).

Diabetes. Fasting insulin was assayed via a sensitive electrochemiluminescent immunoassay; levels of insulin greater than 117
pmol/L were considered at risk. Fasting plasma glucose was assayed with spectrophotometry as part of a comprehensive metabolic panel; glucose levels greater than 5.54 mmol/L were considered at risk. Diabetes was defined as having at-risk levels of insulin or glucose and/or taking a prescription medication for diabetes (51.7% at risk).

Dyslipidemia. Triglycerides and high-density lipoprotein (HDL) cholesterol were assayed as part of a lipid panel via spectrophotometry. At-risk HDL cholesterol was defined as levels <1.03 mmol/L (28.9%); at-risk triglycerides was classified as >1.68 mmol/L (31.5%). At-risk overall cholesterol was defined as being at risk for either HDL or triglycerides or taking cholesterol-lowering medication (72% at risk).

Inflammation. High-sensitivity C-reactive protein, a protein measured in blood that indicates inflammation, was assayed using nephelometry (25). At-risk inflammation was defined as C-reactive protein >28.5 nmol/L (27.5%).

Ischemic heart disease (IHD). Presence/absence of IHD at age 62 (18%) was coded using a validated population-based index (26). Items included self-reported heart attack/myocardial infarction and presence of angina and/or heart surgery (e.g., stent placement, angioplasty, coronary artery bypass). Presence of angina was operationalized as a positive Rose Angina score and/or a prescription for nitroglycerin (27).

Covariates and demographic data. Covariates included age at VETSA 2, lifetime education, ethnicity (white non-Hispanic vs. other), and tobacco smoking (never n = 339, past n = 443, current n = 195). The low-socioeconomic status in family-of-origin demographic variable was operationalized as the father having less than high school education and an occupation of unskilled or semiskilled laborer (28).

Data analysis

Latent growth models (LGMs). LGM analysis was used to estimate the BMI growth patterns/slopes across four time points from early adulthood to late midlife; having four time points allows the quadratic term to be tested in the model.

A two-level unconditional model (a model with only time as a covariate) was analyzed in order to accommodate the repeated measures nested within individuals. The age variable was rescaled by both centering at initial age of 20 and weighting by the time intervals.

Level 1: $BMI_{ij} = \pi_{0i} + \pi_{1i}(age_{ij}-20) + \pi_{2i}(age_{ij}-20)^2 + \epsilon_{ij}$

Level 2: $\pi_{0i} = \beta_{00} + v_{0i}$
$\pi_{1i} = \beta_{10} + v_{1i}$
$\pi_{2i} = \beta_{20} + v_{2i}$

Composite: $BMI_{ij} = \beta_{00} + \beta_{10}(age_{ij}-20) + \beta_{20}(age_{ij}-20)^2 + v_{0i} + v_{1i}(age_{ij}-20) + v_{2i}(age_{ij}-20)^2 + \epsilon_{ij}$

Where $BMI_{ij}$ and $age_{ij}$ represent BMI and age for individual $i$ at $j^{th}$ measurement; $\pi_{0i}$, $\pi_{1i}$, and $\pi_{2i}$ represent individual $i$’s initial BMI, linear growth rate, and quadratic growth rate of BMI; $\epsilon_{ij}$ is level 1 residual and represents the portion of individual $i$’s BMI at $j^{th}$ measurement not accounted for by the model; $\beta_{00}$, $\beta_{10}$, and $\beta_{20}$ represent population average initial BMI, linear growth rate, and quadratic growth rate of BMI; $v_{0i}$, $v_{1i}$, and $v_{2i}$ are level 2 residual and represent deviations from the average initial BMI, linear growth rate, and quadratic growth rate of BMI.

Latent class growth model (LCGM). LCGM analysis was used to identify distinct subgroups with similar BMI change patterns across the four time points. Each latent class consists of specific intercept and slopes allowing linear and quadratic patterns of BMI change. Latent classes were identified starting with one class, then adding another, one at a time. The Lo-Mendell-Rubin likelihood ratio test was used to examine the better fit of (k+1)-class model versus k-class model (k≥1) (29). The significance of the test suggests (k+1)-class model fits the data better. Otherwise, the k-class model fits the data better, and, thus, the k-class model is selected as best fitting.

Empirical Bayes estimates of each individual’s initial BMI (intercept), linear slope, and quadratic slope were calculated and used as predictors in subsequent analyses; Type III results are shown in tables. All subsequent statistical analyses were performed using SAS® version 9.4 (SAS Institute, Cary, North Carolina). Analyses were conducted on dichotomous outcome measures representing risk for hypertension, diabetes, dyslipidemia, inflammation, and IHD at age 62. To examine associations between risk measures at age 62 and BMI intercept and growth rates while controlling for confounding variables, SAS PROC SURVEYREG/PROC SURVEYLOGISTIC was used to account for the twin clustering. Models were adjusted for age, education, ethnicity, smoking, and twin clustering.

All $P$ values are two-tailed; $P$ values < 0.05 were considered statistically significant.

Results

Descriptive data

Participants were predominantly white non-Hispanic (90%). Approximately 25% came from low-socioeconomic-status families. At age 20, participants were typically single (never married) with 12.3 years of education (see Table 1). By age 62, only 5% were single and 78% currently married. Lifetime education was 13.9 years. Mean BMI increased from 22.7 kg/m² (SD 3.0) at baseline, to 25.8 (SD 3.4) at age 40, to 29.3 (SD 4.9) and 29.9 (SD 5.2) at ages 56 and 62, respectively. At baseline, 2.3% of participants had obesity; by age 62, 42% had obesity (28.4%/8.8%/4.9% in levels 1/2/3 obesity, respectively).
TABLE 1 Descriptive data

|                          | Mean (SD) or %                  |
|--------------------------|---------------------------------|
|                          | Age 20 (Baseline) | Age 62 (VETSA 2) |
| Age (y)                  | 19.8 (1.3; range 17-25) | 61.6 (2.4; range 56-66) |
| Ethnicity (% Non-Hispanic white) | 96.2% (2.6%) | 96.6% (2.6%) |
| Marital status (% single) | 92.2% (1.2%) | 93.9% (2.1%) |
| Education (y)            | 12.3 (1.2%) | 13.9 (2.1%) |
| Low-SES family (%)       | 24.7% (5.9%) | 25.9% (6.1%) |
| Systolic BP              | 124.6 (10.8%) | 128.1 (16.1%) |
| Diastolic BP             | 84.2 (8.0%) | 87.6 (9.0%) |
| Height (in)              | 68.9 (2.6%) | 69.1 (2.6%) |
| Weight (lb)              | 153.4 (22.7%) | 203.3 (40.0%) |
| BMI (kg/m²)              | 22.7 (3.0%) | 29.9 (5.2%) |
| Normal BMI (%)           | 741 (75.8%) | 148 (15.2%) |
| Overweight (%)           | 173 (17.7%) | 416 (42.6%) |
| Obesity (%)              | 22 (2.3%) | 412 (42.2%) |
| Level 1                  | 22 (2.3%) | 278 (28.5%) |
| Level 2                  | 0 | 86 (8.8%) |
| Level 3                  | 0 | 43 (4.9%) |
| Smoking (VETSA 2)        | Never | 339 (34.7%) |
|                         | Former | 443 (45.3%) |
|                         | Current | 195 (20.0%) |

Single = never married; BP = blood pressure; ethnicity = non-Hispanic white versus other; low SES = low socioeconomic status; father less than high school education and unskilled/island laborer reported at VETSA 1 (age 56); BMI = body mass index. Normal BMI: ≥18.5 and <25.0 kg/m²; overweight BMI: ≥25 and <30; obesity BMI: ≥30; level 1 obesity: BMI ≥30.0 and <35.0; level 2 obesity: BMI ≥35.0 and <40.0; level 3 obesity: BMI ≥40.0.

TABLE 2 BMI intercept (at age 20) and slope derived from latent growth modeling as predictors of cardiometabolic outcomes at age 62

|                                | Hypertension odds ratio (95% CI) | Diabetes odds ratio (95% CI) | Dyslipidemia odds ratio (95% CI) | Inflammation odds ratio (95% CI) | Ischemic heart disease odds ratio (95% CI) |
|--------------------------------|----------------------------------|------------------------------|----------------------------------|---------------------------------|------------------------------------------|
| Intercept (BMI age 20)          | 1.08 (0.97-1.20) | 1.02 (0.93-1.12) | 0.97 (0.88-1.07) | 1.00 (0.91-1.10) | 0.99 (0.88-1.10) |
| Linear slope                   | 1.28 (1.10-1.50) | 1.34 (1.16-1.54) | 1.33 (1.13-1.57) | 1.25 (1.11-1.41) | 1.21 (1.05-1.39) |
| Quadratic slope                | 3.03 (1.75-5.26) | 1.93 (1.14-3.27) | 3.15 (1.75-5.67) | 3.10 (1.86-5.17) | 1.38 (0.79-2.41) |
| Age (VETSA 2)                  | 1.03 (0.96-1.10) | 1.04 (0.97-1.11) | 1.00 (0.94-1.07) | 1.04 (0.98-1.12) | 0.93 (0.86-1.01) |
| Education (lifetime years)     | 1.02 (0.94-1.11) | 1.00 (0.93-1.08) | 0.97 (0.89-1.05) | 1.04 (0.96-1.13) | 0.99 (0.89-1.07) |
| Ethnicity (non-Hispanic white vs. other) | 1.06 (0.62-1.81) | 1.01 (0.63-1.62) | 1.36 (0.79-2.33) | 0.82 (0.49-1.36) | 1.12 (0.61-2.07) |
| Smoking (VETSA 2)              | Current smokers vs. never smokers | 0.98 (0.61-1.57) | 0.90 (0.58-1.38) | 1.51 (0.94-2.44) | 2.96 (1.92-4.56) |
|                                | Former smokers vs. never smokers | 1.16 (0.80-1.69) | 1.20 (0.85-1.69) | 1.17 (0.82-1.65) | 1.00 (0.69-1.46) |

BMI = body mass index (kg/m²); inflammation measured with high-sensitivity C-reactive protein; models include intercept (age 20 BMI), age (years), education (lifetime years), ethnicity (0 = other; 1 = non-Hispanic white), and smoking (0 = never smokers; 1 = former smokers; 2 = current smokers; never smoker as reference group) as covariates in models with family as a random effect. Bold indicates values significant with 95% confidence interval (CI). Age measured in years. Age centered at 20 years. VETSA 2 measures = age 62; BMI intercept and slope derived from empirical Bayes estimates.

LGM of BMI change

An unconditional LGM with fixed and random effects for the intercept, linear, and quadratic slopes provided the best fit to the data (details in Supporting Information Table S1). Fixed effect estimates were significant for the intercept (β = 22.64; P < 0.0001), linear (β = 3.20; P < 0.0001), and quadratic slopes (β = 0.22; P = 0.002), respectively, indicating an average BMI of 22.64 at age 20 years, with a positive linear increase of 3.2 BMI units every two decades at the centering age of 20 years and accelerating BMI increase of 0.22 BMI units every two decades across the age range.

Individual-level intercepts and slopes were used to estimate risk for cardiometabolic outcomes at age 62. In models adjusting for age, education, ethnicity, smoking, and twin clustering, BMI linear and quadratic slopes were both significantly associated with risk for hypertension, diabetes, dyslipidemia, and inflammation (Table 2). The significant positive quadratic effect indicates that an accelerated increase in BMI was associated with poorer outcomes. When both linear and quadratic slopes were significantly associated with outcomes, odds ratios (OR) ranged from 1.25 (inflammation) to 1.34 (diabetes) for the linear slope and from 1.93 (diabetes) to 3.15 (dyslipidemia) for the quadratic slope. Prevalence of IHD was associated with linear, but not quadratic, BMI slope. As indicated by the odds ratios for intercept, BMI20 did not predict any age 62 outcomes. Current and past smokers were at higher risk for IHD; odds ratios for current smoking and inflammation were also significant. No other covariates were significantly associated with the cardiometabolic outcomes.

Because individuals with a steeper slope would tend to have higher BMI62, it could be that it is only useful to know BMI62 and not rate of change over time. To address this question, we first examined cross-sectional associations between BMI62 and outcomes. Cross-sectional associations between BMI62 and cardiometabolic outcomes were all significant (Table 3).

We then examined the effect of the LGM-derived slope variables and BMI62 when both variables were in the same model. For those
models, we recentered the LGM analyses at age 62. By examining Type III effects, these models allowed us to test whether slope was uniquely associated with outcomes over and above BMI62 (Table 4). There were significant odds ratios for linear slope for diabetes (OR = 1.29) and dyslipidemia (OR = 1.42). Odds ratios for BMI62 were all close to 1.00 and nonsignificant. Smoking was the only other variable that was a significant unique predictor; the odds ratio was 2.96 for hypertension and 2.79 for IHD for current versus never smokers and 2.83 for IHD for former versus never smokers. There were no significant odds ratios for either slope measure or BMI62 for hypertension, inflammation, and IHD. However, it seems likely this lack of significance is due to collinearity rather than the fact that these measures are not predictive of change.

**LCGMs and heterogeneity of change**

LCGMs were tested to determine the number of distinct latent classes best representing the longitudinal BMI data. Using the Lo-Mendell-Rubin test as the index of model fit, the best-fitting model identified three BMI trajectory classes/trajectories (Figure 1 and Table 5). Terms for intercept, linear, and quadratic slope for trajectories 2 and 3 were significant, but for trajectory 1, only the intercept and linear terms were significant.

As can be seen in Figure 1, trajectory 1 (N = 490, 50%) had the lowest BMI at all time points; baseline BMI was 21.26 kg/m² (SD 2.1), rising to 26.1 (SD 5.2) by age 62. Trajectory 2 (N = 400; 41%) baseline BMI was in the normal range (23.6, SD 2.7), rising to level 1 obesity (mean BMI 32.1, SD 2.5) by age 62. Trajectory 3 (N = 79; 9%) was overweight at baseline (mean BMI 26.3, SD 3.5), increased to level 1 obesity by age 40, and reached level 3 obesity by age 62 (mean BMI 41.0, SD 4.2). Significant quadratic terms for trajectories 2 and 3 indicate accelerating BMI over time.

**Odds ratios for rates of cardiometabolic outcomes associated with the three BMI trajectories are shown in Table 6. Compared with trajectory 1, trajectory 2 had significantly greater risk for**

### TABLE 3 Cross-sectional associations between BMI at age 62 and cardiometabolic outcomes at age 62

|                        | Hypertension odds ratio (95% CI) | Diabetes odds ratio (95% CI) | Dyslipidemia odds ratio (95% CI) | Inflammation odds ratio (95% CI) | Ischemic heart disease odds ratio (95% CI) |
|------------------------|----------------------------------|------------------------------|----------------------------------|----------------------------------|-------------------------------------------|
| Intercept (BMI age 20) | 0.99 (0.89-1.09)                 | 0.92 (0.83-1.01)             | 0.87 (0.79-0.97)                 | 0.93 (0.83-1.03)                 | 0.93 (0.82-1.05)                          |
| BMI age 62             | 1.15 (1.10-1.21)                 | 1.14 (1.09-1.18)             | 1.17 (1.11-1.24)                 | 1.14 (1.10-1.19)                 | 1.08 (1.02-1.13)                          |
| Age (VETSA 2)          | 1.03 (0.96-1.10)                 | 1.04 (0.97-1.11)             | 1.00 (0.93-1.07)                 | 1.04 (0.97-1.11)                 | 0.93 (0.86-1.01)                          |
| Education (lifetime years) | 1.02 (0.94-1.11)             | 1.00 (0.93-1.08)             | 0.97 (0.90-1.06)                 | 1.04 (0.97-1.13)                 | 0.98 (0.89-1.07)                          |
| Ethnicity (non-Hispanic white vs. other) | 1.04 (0.61-1.78)             | 0.98 (0.62-1.57)             | 1.33 (0.78-2.26)                 | 0.81 (0.49-1.35)                 | 1.10 (0.60-2.02)                          |
| Smoking (age 62)       |                                  |                              |                                  |                                  |                                           |
| Current smokers vs. never smokers | 0.99 (0.62-1.58)             | 0.90 (0.59-1.39)             | 1.53 (0.94-2.47)                 | 2.94 (1.91-4.52)                 | 2.61 (1.59-4.98)                          |
| Former smokers vs. never smokers | 1.16 (0.80-1.69)            | 1.20 (0.86-1.69)             | 1.16 (0.82-1.64)                 | 1.00 (0.69-1.46)                 | 2.85 (1.79-4.52)                          |

BMI = body mass index (kg/m²); inflammation measured with high-sensitivity C-reactive protein; models include intercept (age 20 BMI), age (years), education (years), ethnicity (0 = other; 1 = non-Hispanic white), and smoking (0 = never smokers; 1 = former smokers; 2 = current smokers; never smoker = reference group) as covariates in models with family as a random effect. Bold indicates values significant with 95% confidence interval (CI). Age measured in years. VETSA 2 measures = age 62.

### TABLE 4 BMI intercept (at age 62) and slope derived from latent growth modeling as predictors of cardiometabolic outcomes at age 62

|                        | Hypertension odds ratio (95% CI) | Diabetes odds ratio (95% CI) | Dyslipidemia odds ratio (95% CI) | Inflammation odds ratio (95% CI) | Ischemic heart disease odds ratio (95% CI) |
|------------------------|----------------------------------|------------------------------|----------------------------------|----------------------------------|-------------------------------------------|
| Intercept (BMI age 62) | 1.08 (0.97-1.20)                 | 1.02 (0.93-1.12)             | 0.97 (0.88-1.07)                 | 1.00 (0.91-1.10)                 | 0.99 (0.88-1.10)                          |
| Linear slope (BMI)     | 1.10 (0.88-1.38)                 | 1.29 (1.05-1.60)             | 1.42 (1.13-1.80)                 | 1.25 (0.99-1.58)                 | 1.24 (0.94-1.63)                          |
| Quadratic slope (BMI)  | 1.48 (0.65-3.40)                 | 0.63 (0.28-1.42)             | 0.85 (0.36-1.98)                 | 1.24 (0.59-2.63)                 | 0.61 (0.25-1.46)                          |
| Age (VETSA 2)          | 1.03 (0.96-1.10)                 | 1.04 (0.97-1.11)             | 1.00 (0.94-1.07)                 | 1.04 (0.98-1.12)                 | 0.93 (0.86-1.01)                          |
| Education (lifetime years) | 1.02 (0.94-1.11)             | 1.00 (0.93-1.08)             | 0.97 (0.89-1.05)                 | 1.04 (0.96-1.13)                 | 0.98 (0.89-1.07)                          |
| Ethnicity (non-Hispanic white vs. other) | 1.06 (0.62-1.81)             | 1.01 (0.63-1.62)             | 1.36 (0.79-2.33)                 | 0.82 (0.49-1.36)                 | 1.12 (0.61-2.07)                          |
| Smoking (VETSA 2)      |                                  |                              |                                  |                                  |                                           |
| Current smokers vs. never smokers | 0.98 (0.61-1.57)             | 0.90 (0.58-1.38)             | 1.51 (0.94-2.44)                 | 2.96 (1.92-4.56)                 | 2.79 (1.57-4.94)                          |
| Former smokers vs. never smokers | 1.16 (0.80-1.69)            | 1.20 (0.85-1.69)             | 1.17 (0.82-1.65)                 | 1.00 (0.69-1.46)                 | 2.83 (1.79-4.50)                          |

BMI = body mass index (kg/m²); inflammation measured with high-sensitivity C-reactive protein; models include intercept (age 20 BMI), age (years), education (lifetime in years), ethnicity (0 = other; 1 = non-Hispanic white), and smoking (0 = never smokers; 1 = former smokers; 2 = current smokers; never smoker = reference group) as covariates in models with family (twin clustering) as a random effect. Bold indicates values significant with 95% confidence interval (CI). Age measured in years. Age centered at 62 years. VETSA 2 measures = age 62; BMI intercept and slope derived from empirical Bayes estimates.
hypertension, diabetes, dyslipidemia, and high inflammation but not IHD; odds ratios ranged from 1.81 (diabetes) to 2.31 (hypertension). Trajectory 3, compared with trajectory 1, had significantly higher risks for all outcomes; odds ratios ranged from 1.86 (IHD) to 8.08 (hypertension). Trajectory 3, compared with trajectory 2, had significantly greater risk for hypertension (OR \(5^{3.49}\)), diabetes (OR \(5^{1.69}\)), and inflammation (OR \(5^{2.29}\)) but not dyslipidemia or IHD. After applying the false discovery rate adjustment (31), all comparisons remained significant except for the odds ratio of IHD (trajectory 1 vs. 3). Descriptive data for the trajectories are in Supporting Information Tables S2 and S3.

**Discussion**

Across four decades, men with accelerated increases in BMI were at significantly higher risk for hypertension, diabetes, dyslipidemia, and inflammation at age 62, regardless of young adult BMI. Latent class growth curve analyses identified three latent classes representing BMI trajectories. Comparisons of the three trajectories revealed health benefits for participants who maintained BMI at lower and relatively stable levels. Trajectory 1, with an average change of 5 kg/m\(^2\) across four decades, had the lowest levels of cardiometabolic risks. Trajectory 3, with three out of four time points at obesity levels and an average change of 15 kg/m\(^2\), had significantly higher risk for all outcomes except IHD compared with other trajectories. However, even moderate increases in BMI as shown by trajectory 2 (average change of 9 kg/m\(^2\)) put participants at higher risk. In the Framingham Heart Study, men with no cardiometabolic risk factors at midlife were highly unlikely to develop heart disease and had better survival in late life (5). Maintaining BMI close to the normal range may be one path contributing to lower cardiometabolic risks. Higher BMI, but also more rapidly increasing BMI, appears to reflect increased cardiometabolic risks.

In models that simultaneously included slopes and BMI62 (Table 4), linear slope had unique predictive value for diabetes and dyslipidemia after accounting for BMI62, indicating that rate of change (i.e., how one got to BMI62) and not just where one ended up makes a difference with respect to these outcomes. Slope measures had significant odds ratios for all outcomes in LGMs with slope and BMI20 (Table 2); there were significant odds ratios for BMI62 for all cardiometabolic outcomes in cross-sectional analyses (Table 3), and trajectory comparisons showed significant odds ratios for cardiometabolic outcomes (Table 6). As such, we think the most parsimonious explanation is that results including BMI62 as an intercept are due to collinearity rather than the fact that the slope measures or BMI62 are not predictive of hypertension, inflammation, or IHD.

These results have potential implications for cognitive and brain health in later life. Obesity and metabolic dysregulation appear to be

**Figure 1** Three latent class trajectory (Traj.) groups representing change in body mass index (BMI) from age 20 (T0) to age 40 (T1), age 56 (T2), and age 62 (T3). [Color figure can be viewed at wileyonlinelibrary.com]

**TABLE 5** Latent class growth modeling over four time points with linear and quadratic terms

| Model | Entropy | LMR | LMR \(P^{0.052}\) |
|-------|---------|-----|-------------------|
| 1     | 0.90    | 1610.66 | 0.0052 |
| 2     | 0.86    | 821.02  | 0.0003 |
| 3     | 0.85    | 373.01  | 0.3040 |

3-class model parameters

| Class 1 (\(N = 490\)) | Class 2 (\(N = 400\)) | Class 3 (\(N = 87\)) |
|------------------------|------------------------|------------------------|
| Intercept              | 21.26 (CI: 20.99 to 21.53)** | 23.52 (CI: 23.13 to 23.92)** | 26.25 (CI: 25.17 to 27.34)** |
| Linear                 | 2.66 (CI: 2.28 to 3.05)**  | 3.31 (CI: 2.84 to 3.78)**  | 5.65 (CI: 3.85 to 7.44)**  |
| Quadratic              | \(-0.10\) (CI: \(-0.26\) to 0.05)** | 0.47 (CI: 0.24 to 0.69)**  | 0.91 (CI: 0.05 to 1.78)**  |

CI = confidence interval; LMR = Lo-Mendell-Rubin likelihood ratio test; model 3 (3-class model, bold font) has best fit. In the text, to avoid confusion, class 1 corresponds to trajectory 1; class 2 to trajectory 2; class 3 to trajectory 3.

\(^{*}P < 0.04; ^{*}{*}P < 0.001.\)
TABLE 6 Comparisons between trajectory groups for cardiometabolic outcomes at age 62

| BMI trajectory group | Hypertension odds ratio (95% CI) | Diabetes odds ratio (95% CI) | Dyslipidemia odds ratio (95% CI) | High inflammation odds ratio (95% CI) | Ischemic heart disease odds ratio (95% CI) |
|----------------------|----------------------------------|-----------------------------|----------------------------------|--------------------------------------|-------------------------------------------|
| 2 vs. 1              | 2.31 (1.62-3.30)                 | 1.81 (1.34-2.45)            | 1.92 (1.39-2.65)                 | 2.08 (1.49-2.91)                     | 1.41 (0.95-2.09)                         |
| 3 vs. 1              | 8.08 (2.70-24.00)               | 3.06 (1.80-5.22)            | 3.44 (1.58-7.49)                 | 4.77 (2.85-7.99)                     | 1.86 (1.02-3.39)                         |
| 3 vs. 2              | 3.49 (1.16-10.53)               | 1.69 (1.01-2.85)            | 1.80 (0.82-3.95)                 | 2.29 (1.40-3.76)                     | 1.32 (0.75-2.31)                         |

BMI = body mass index (kg/m²). CI = confidence interval; trajectory 1 (N = 490); trajectory 2 (N = 400); trajectory 3 (N = 87); bold indicates values significant with 95% CI. Models adjusted for age, education, ethnicity, smoking, and twin clustering. Ischemic heart disease no longer significant after adjusting for false discovery rate (P = 0.13).

Related to Alzheimer’s disease pathophysiology; having overweight or obesity in midlife appears to be detrimental for late-life cognition, brain structure, and brain function (32). In the Whitehall II study of midlife adults through average age 61, higher BMI was associated with poorer cognition; age 61 cognitive effects were stronger for those who had obesity at two of three time points (33). Shared genetic factors are also implicated in the association between BMI and cognitive function (34,35). For instance, in a genome-wide association study meta-analysis, the most strongly enriched gene sets for BMI and obesity involved critical brain pathways regulating appetite, insulin synthesis and processing, and energy metabolism in the hypothalamus and pituitary as well as synaptic plasticity and cellular mechanisms mediating learning and memory in the hippocampus (35). Finally, adults ages 50 to 75 self-reporting larger weight gain in adulthood had significantly shorter telomeres, a potential biomarker for aging (36).

A limitation of our study is that height and weight were self-reported at age 40, which may influence growth curves (21,22). On the other hand, having objectively measured BMI at three of the four time points is a strength. Waist circumference is sometimes considered a better indicator of adiposity than BMI; however, we had only two time points with waist circumference measures, thus not allowing for growth curve analyses (37). Moreover, BMI and waist circumference were correlated 0.90, and cross-sectional results at age 62 (not shown) were virtually the same. The sample is primarily non-Hispanic white male veterans, so generalizability to women and other groups is unclear; recent longitudinal studies found some sex differences in associations with BMI (38). It is a strength that VETSA comprises a national sample of male veterans, but their military service meant that they were healthy at baseline. Despite initial selection for good health, sample demographics and health statistics paralleled CDC and census statistics for US men. In addition, veterans are an often overlooked cohort of adults (39). Given that this is a twin sample, there may be greater homogeneity than would be expected in a non-vet study. Finally, we do not address genetic and environmental influences on BMI change, which may contribute to differential vulnerability; BMI is highly heritable and different genes may affect BMI at different ages (14,40).

Despite these limitations, this study—to our knowledge—is unique in the richness of its longitudinal BMI data starting in young adulthood and its objectively measured metabolic outcomes at late midlife. This large age-homogeneous sample allowed for in-depth examination of BMI change and heterogeneity across an important transitional age period when cardiometabolic dysregulation and cardiovascular disease become more prevalent (35). Studies focused on only elderly adults may already have high levels of selective attrition due to high morbidity and mortality associated with obesity, especially among men. We provided evidence from multiple analytic approaches that increases in BMI—in particular, accelerated change—from young adulthood to midlife are significantly associated with risk for poorer cardiometabolic outcomes.

Acknowledgments

Content of this manuscript is the responsibility of the authors and does not represent official views of the National Institutes of Health or the Veterans’ Administration. The US Department of Veterans Affairs, Department of Defense; National Personnel Records Center, National Archives and Records Administration; Internal Revenue Service; National Opinion Research Center; National Research Council, National Academy of Sciences; and the Institute for Survey Research, Temple University provided invaluable assistance in the conduct of the VETR. The authors gratefully acknowledge the continued cooperation of the twins and the efforts of many staff members.

© 2017 The Obesity Society

References

1. Olshansky SJ, Passaro DJ, Hershov RC, et al. A potential decline in life expectancy in the united states in the 21st century. N Engl J Med 2005;352:1138-1145.
2. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the national health and nutrition examination survey, 1999 to 2004. J Am Coll Surg 2008;207:928-934.
3. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.
4. Reis JP, Allen N, Gunderson EP, et al. Excess body mass index and waist circumference-years and incident cardiovascular disease: the cardio study. Obesity 2015;23:879-885.
5. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-798.
6. Twigg G, Yaniv G, Levine H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med 2016;374:2430-2440.
7. Murray CJ, Atkinson C, Bhailla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608.
8. Flegel KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999-2010. JAMA 2012;307:491-497.
9. Flegel KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016;315:2284-2291.
10. Østbye T, Malhotra R, Landerman LR. Body mass trajectories through adulthood: results from the national longitudinal survey of youth 1979 cohort (1981–2006). *Int J Epidemiol* 2011;40:240-250.

11. Norman J, Bild D, Lewis C, Liu K, West DS. The impact of weight change on cardiovascular disease risk factors in young black and white adults: the CARDIA study. *Int J Obes* 2003;27:369-376.

12. Dowd JB, Zajacova A. Long-term obesity and cardiovascular, inflammatory, and metabolic risk in us adults. *Am J Prev Med* 2014;46:578-584.

13. Tirosch A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. *N Engl J Med* 2011;364:1315-1325.

14. Franz CE, Grant MD, Jacobson KC, et al. Genetics of body mass stability and risk for chronic disease: a 28-year longitudinal study. *Twin Res Hum Genet* 2007;10:537-545.

15. Panizzon MS, Hauger RL, Sailors M, et al. A new look at the genetic and environmental coherence of metabolic syndrome components. *Obesity* 2015;23:2499-2507.

16. Kremen WS, Franz CE, Lyons MJ. VETSA: The Vietnam Era Twin Study of Aging. *Twin Res Hum Genet* 2013;16:399-402.

17. Eisen SA, True WR, Goldberg J, Henderson W, Robinette CD. The Vietnam Era Twin (VET) Registry: method of construction. *Acta Genet Med Gemellol (Roma)* 1987;36:61-66.

18. Kremen WS, Thompson-Brenner H, Leung YJ, et al. Genes, environment, and time: The Vietnam Era Twin Study of Aging (VETSA). *Twin Res Hum Genet* 2006;9:1009-1022.

19. Schoenborn CA, Heyman KM. Health characteristics of adults aged 55 years and over: United States, 2004-2007. National Health Statistics Reports, no. 16. Hyattsville, MD: National Center for Health Statistics; 2009.

20. Goldberg J, Curran B, Vitek ME, Henderson WG, Boyko EJ. The Vietnam Era Twin Registry. *Twin Res* 2002;5:476-481.

21. Connor-Gorber S, Tremblay A, Moher D, Gorber B. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. *Obes Rev* 2007;8:307-326.

22. Villanueva EV. The validity of self-reported weight in US adults: A population based cross-sectional study. *BMC Public Health* 2001;1:11. doi:10.1186/1471-2458-1-11

23. Flegal KM, Kit BK, Graubard BI. Body mass index categories in observational studies of weight and risk of death. *Am J Epidemiol* 2014;180:288-296.

24. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College Of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation* 2011;123:2434-2506.

25. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. *Clin Chem* 2009;55:219-228.

26. Xian H, Scherzer JF, Franz CE, et al. Genetic vulnerability and phenotypic expression of depression and risk for ischemic heart disease in the Vietnam era twin study of aging. *Psychosom Med* 2010;72:370-375.

27. Lampe FC, Walker M, Lennon LT, Whincup PH, Ebrahim S. Validity of a self-reported history of doctor-diagnosed angina. *J Clin Epidemiol* 1999;52:73-81.

28. Hollingshead AB, Redlich FC. Social class and mental illness: A community study. 1958. *Am J Public Health* 1997;97:1756-1757.

29. Lo Y, Mendell N, Rubin D. Testing the number of components in a normal mixture. *Biometrika* 2001;88:767-778.

30. Muthén LK, Muthén BO. *Mplus User’s Guide*. 7th ed. Los Angeles, CA: Muthén & Muthén; 2015.

31. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289-300.

32. Bischof GN, Park DC. Obesity and aging: consequences for cognition, brain structure, and brain function. *Psychosom Med* 2015;77:697-709.

33. Singh-Manoux A, Czernichow S, Elbaz A, et al. Obesity phenotypes in midlife and cognition in early old age: the Whitehall II cohort study. *Neurology* 2012;79:755-762.

34. Marioni RE, Yang J, Dykert D, et al. Assessing the genetic overlap between BMI and cognitive function. *Mol Psychiatry* 2016;21:1477-1482.

35. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518:197-206.

36. Muezzinler A, Mons U, Dieffenbach AK, et al. Body mass index and leukocyte telomere length dynamics among older adults: results from the ESTHER cohort. *Exp Gerontol* 2015;74:1-8.

37. Flegal KM, Shepherd JA, Looker AC, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. *Am J Clin Nutr* 2009;89:500-508.

38. von Bonderoff MB, Tormakangas T, Rantanen T, et al. Early life body mass trajectories and mortality in older age: findings from the Helsinki Birth Cohort Study. *Ann Med* 2015;47:34-39.

39. Department of Veterans Affairs Office of the Actuary. The veteran population projection model 2011 (VetPop2011). 2013.

40. Jelenkovic A, Yokoyama Y, Sund R, et al. Zygosity differences in height and body mass index of twins from infancy to old age: a study of the CODATwins project. *Twin Res Hum Genet* 2015;18:557-570.